title: Aminoguanidine administered during the induction of oral tolerance alters the systemic response of the tolerised rats.
abstract: Herewith we investigated the role of nitric oxide synthase (NOS)-II in the establishment of oral tolerance induced by low antigen dose. To accomplish this, we used a rat model of oral tolerance induced by intragastric administration of low doses of ovalbumin (OVA). NOS-II was inhibited in vivo during the onset of tolerance by intraperitoneal (i.p.) treatment with aminoguanidine (AMG), a selective NOS-II inhibitor. Four experimental groups were generated: (TOL), tolerised rats, receiving OVA but no AMG; (TAG), rats tolerised with OVA and simultaneously receiving AMG i.p.; (CAG), controls treated with AMG but no oral antigen; and (CONT), controls receiving neither OVA nor AMG treatment. The state of oral tolerance was evaluated in all groups by analysing several immune parameters upon subcutaneous administration of OVA in Freund's complete adjuvant. First, we were able to determine that NOS-II inhibition altered the TH1/TH2 balance in tolerised rats, driving the TH2 anti-OVA response in TOL rats towards TH1 in TAG animals, which showed enhanced delayed hypersensitivity responses. Second, splenocyte cultures from TAG rats showed lower levels of IL-10 production compared to TOL samples as determined by ELISA analysis. Last, we detected the presence of a functional distinct Tr1 regulatory T cell population in spleen samples recovered from TAG animals. Contrary to what happened with TOL Tr1 cells, the levels of Tr1 cells in TAG samples were modified by in vitro stimulation with OVA. All together, these data indicate a preponderant role for NOS-II in the process of oral tolerance induced by low antigen dose.
authors.affiliation: Laboratory of Immunochemistry, Dept. of Biological Chemistry, Faculty of Sciences, University of Buenos Aires, Argentina. lili@qb.fcen.uba.ar
authors.forename: Liliana G
authors.initials: LG
authors.lastname: Franco
authors.forename: Catalina A
authors.initials: CA
authors.lastname: Feledi
authors.forename: Ernesto J
authors.initials: EJ
authors.lastname: Massouh
authors.forename: Fabian
authors.initials: F
authors.lastname: Benencia
mesh_terms: D000284:Administration, Oral; D000818:Animals; D002478:Cells, Cultured; D002645:Chickens; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006146:Guanidines / Q000008:administration & dosage*; D007108:Immune Tolerance / Q000187:drug effects*; D007274:Injections, Intraperitoneal; D023421:Models, Animal; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors; D010047:Ovalbumin / Q000276:immunology; D051381:Rats; D017208:Rats, Wistar; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology; D018418:Th2 Cells / Q000187:drug effects / Q000276:immunology
chemical_list: D004791:Enzyme Inhibitors; D006146:Guanidines; D010047:Ovalbumin; D052247:Nitric Oxide Synthase Type II; C004479:pimagedine